TRANSVAC2: Funding for European vaccine research infrastructure

The European Commission (EC), in the context of the Horizon 2020 Framework Programme, commits significant funding to TRANSVAC2, a European vaccine research and development (R&D) infrastructure.

Dr Odile Leroy, Executive Director of the European Vaccine Initiative (EVI) and coordinator of TRANSVAC2, said: “The TRANSVAC2 activities will further strengthen the vaccine R&D infrastructure in Europe and will thereby accelerate the development of effective vaccines that are urgently needed to address global health challenges”.

The call for applications will be launched on 15 October 2017, the first cut-off date for submission of service applications will be 15 December 2017, followed by subsequent cut-off dates every four months.

For more info: click here